文献速递帕金森病与运动障碍认知障碍与痴呆

进行性核上性麻痹与皮质基底节综合征谱系的诊断研究

Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome.
PubMed 文献 · JAMA Neurol · 2020-01-01

该队列研究纳入英国运动障碍门诊的222例非典型帕金森综合征患者(101例PSP、55例MSA、40例CBS及26例不确定),并与PD患者及年龄匹配对照比较,采用临床轨迹、认知量表、血清NF-L、基因型及MRI体积测量区分亚型。应用MDS-PSP诊断标准使PSP诊断数从58增至101例,近半数非经典型;脑脊液分析识别出CBS-AD亚型。各亚型具有可助早期诊断的 distinct 特征。

要点

  • 应用MDS-PSP新标准可使PSP诊断数近乎翻倍,近半数非经典型PSP-RS。
  • PSP-皮质下型诊断延迟更长、临床轨迹更良性,可与PSP-RS及皮质型区分。
  • 血清NF-L可区分PD与全部PSP及CBS合并病例(AUC 0.80)。

核心结论

  • 仅关注PSP-RS亚型的研究可能遗漏大量具有PSP tau病理的患者。
  • 脑脊液分析定义了独立的CBS-AD亚型。
  • PSP与CBS各亚型具有可助早期诊断的 distinct 特征。

研究设计与样本

  • 多中心队列研究,2015年9月1日至2018年12月1日从英国运动障碍门诊招募患者。
  • 纳入222例APS患者(101例PSP、55例MSA、40例CBS、26例不确定),男129例(58.1%),平均年龄68.3(SD 8.7)岁。
  • 另纳入年龄匹配对照76例及PD患者1967例进行比较。
  • APS患者按亚型分层:PSP-RS、PSP-皮质下、PSP-皮质、MSA-帕金森型、MSA-小脑型、CBS-AD、CBS-非AD。

主要发现

  • 13例接受尸检的PSP和CBS患者中12例(92.3%)生前临床诊断与病理诊断一致。
  • PSP-皮质下组诊断延迟更长且临床轨迹较PSP-RS和PSP-皮质组更良性。
  • PSP-皮质下组与PSP-皮质及PSP-RS组可通过皮质MRI体积测量(AUC 0.84-0.89)、认知特征(AUC 0.80-0.83)、血清NF-L水平(AUC 0.75-0.83)及TRIM11 rs564309基因型区分。
  • 中脑萎缩是所有PSP组的共同特征;17例接受脑脊液分析的CBS患者中8例(47.1%)为CBS-AD亚型。

关键数值与推荐

  • CBS-AD组较CBS-非AD组诊断延迟更长、临床轨迹相对良性、认知损害更重、APOE-ε4等位基因频率更高(AUC 0.80-0.87;P < .05)。
  • 血清NF-L水平区分PD与全部PSP及CBS合并病例的AUC为0.80(P < .05)。

临床怎么用

  • 应使用MDS-PSP新诊断标准以识别非经典PSP亚型,避免遗漏。
  • 对CBS患者考虑脑脊液分析以识别CBS-AD亚型。
  • 联合皮质MRI体积测量、认知评估、血清NF-L及基因型有助于PSP亚型早期区分。

局限性

  • 仅部分患者接受尸检或脑脊液分析,病理确诊与脑脊液亚型分类样本量有限。
  • 研究为观察性队列,亚型区分指标的诊断效能需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Atypical parkinsonian syndromes (APS), including progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA), may be difficult to distinguish in early stages and are often misdiagnosed as Parkinson disease (PD). The diagnostic criteria for PSP have been updated to encompass a range of clinical subtypes but have not been prospectively studied. OBJECTIVE: To define the distinguishing features of PSP and CBS subtypes and to assess their usefulness in facilitating early diagnosis and separation from PD. DESIGN, SETTING, PARTICIPANTS: This cohort study recruited patients with APS and PD from movement disorder clinics across the United Kingdom from September 1, 2015, through December 1, 2018. Patients with APS were stratified into the following groups: those with Richardson syndrome (PSP-RS), PSP-subcortical (including PSP-parkinsonism and progressive gait freezing subtypes), PSP-cortical (including PSP-frontal and PSP-CBS overlap subtypes), MSA-parkinsonism, MSA-cerebellar, CBS-Alzheimer disease (CBS-AD), and CBS-non-AD. Data were analyzed from February 1, through May 1, 2019. MAIN OUTCOMES AND MEASURES: Baseline group comparisons used (1) clinical trajectory; (2) cognitive screening scales; (3) serum neurofilament light chain (NF-L) levels; (4) TRIM11, ApoE, and MAPT genotypes; and (5) volumetric magnetic resonance imaging measures. RESULTS: A total of 222 patients with APS (101 with PSP, 55 with MSA, 40 with CBS, and 26 indeterminate) were recruited (129 [58.1%] male; mean [SD] age at recruitment, 68.3 [8.7] years). Age-matched control participants (n = 76) and patients with PD (n = 1967) were included for comparison. Concordance between the antemortem clinical and pathologic diagnoses was achieved in 12 of 13 patients with PSP and CBS (92.3%) undergoing postmortem evaluation. Applying the Movement Disorder Society PSP diagnostic criteria almost doubled the number of patients diagnosed with PSP from 58 to 101. Forty-nine of 101 patients with reclassified PSP (48.5%) did not have the classic PSP-RS subtype. Patients in the PSP-subcortical group had a longer diagnostic latency and a more benign clinical trajectory than those in PSP-RS and PSP-cortical groups. The PSP-subcortical group was distinguished from PSP-cortical and PSP-RS groups by cortical volumetric magnetic resonance imaging measures (area under the curve [AUC], 0.84-0.89), cognitive profile (AUC, 0.80-0.83), serum NF-L level (AUC, 0.75-0.83), and TRIM11 rs564309 genotype. Midbrain atrophy was a common feature of all PSP groups. Eight of 17 patients with CBS (47.1%) undergoing cerebrospinal fluid analysis were identified as having the CBS-AD subtype. Patients in the CBS-AD group had a longer diagnostic latency, relatively benign clinical trajectory, greater cognitive impairment, and higher APOE-ε4 allele frequency than those in the CBS-non-AD group (AUC, 0.80-0.87; P < .05). Serum NF-L levels distinguished PD from all PSP and CBS cases combined (AUC, 0.80; P < .05). CONCLUSIONS AND RELEVANCE: These findings suggest that studies focusing on the PSP-RS subtype are likely to miss a large number of patients with underlying PSP tau pathology. Analysis of cerebrospinal fluid defined a distinct CBS-AD subtype. The PSP and CBS subtypes have distinct characteristics that may enhance their early diagnosis.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Jabbari E, Holland N, Chelban V, et al. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurol. 2020. PMID: 31860007. doi:10.1001/jamaneurol.2019.4347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。